TNF Pharmaceuticals, Inc. (Nasdaq: TNFA)

TNF Pharmaceuticals, Inc., formerly MyMD Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on developing therapies for age-related diseases and autoimmune or inflammatory conditions. The company’s lead programs target tumor necrosis factor-alpha (TNF-α) to address underlying causes rather than solely symptoms.

---

Corporate Structure

• Headquarters: Baltimore, Maryland
• Employees: 11 – 50
• Leadership:
  • Mitchell Glass, M.D., President & Chief Medical Officer
• Public Listing:
  • Exchange: Nasdaq Capital Market
  • Ticker: TNFA (effective July 24, 2024)
• Partnerships & Technology:
  • Collaboration with Renova Health for AI-driven patient identification and trial design
  • Investor relations site:

---

Recent Developments

• Corporate Rebranding

  • July 22, 2024: MyMD Pharmaceuticals, Inc. changed its name to TNF Pharmaceuticals, Inc.
  • July 24, 2024: Began trading under “TNFA” on Nasdaq.

• Pipeline Progress

  • MYMD-1® (oral TNF-α inhibitor):
    • Phase 2 study completed in 2023, evaluating safety and efficacy in sarcopenia with statistically significant results.
    • Mid-stage trials initiated for age-related and inflammatory conditions.
  • Supera-CBD (synthetic cannabidiol analog): Early-stage studies targeting chronic pain, addiction, and epilepsy.

• Investor & Industry Events

  • Participation in the 2025 Biocytogen Symposium on drug discovery strategies.

---

Financial and Strategic Analysis

Stock Metrics (as of June 10, 2025)

Metric	Value
Last Price	$0.2274
Daily Change	+34.56%
Volume	6,059,422
Average Volume (TTM)	2,395,115
Market Capitalization (intraday)	$3.24 M
52-Week Range	$0.1510 – $2.2400
Beta (5 Y Monthly)	2.42
EPS (TTM)	– 6.37
Net Income (TTM)	– $18.1 M
Cash & Equivalents (MRQ)	$5.88 M
Total Debt/Equity (MRQ)	0.02%
Levered Free Cash Flow (TTM)	– $3.17 M

Strategic Positioning

• Oral TNF-α Inhibition

  • MYMD-1 is the only orally dosed TNF-α inhibitor in clinical development, distinguishing it from injectable biologics such as etanercept and infliximab.
  • The potential for dose adjustment based on patient response and safety profiles is a distinct feature.

• Second Platform

  • Supera-CBD is developed as a synthetic CBD analog with high potency for conditions not fully addressed by existing CBD products.

• Balance Sheet

  • Cash runway supported by $5.88 M in cash with minimal debt, reflecting ongoing R&D expenditure.

---

Market Position and Industry Context

• Competitive Landscape

  • Established TNF-α blockers dominate the autoimmune market, but there is no approved oral small-molecule alternative.
  • TNF Pharmaceuticals holds a niche position with its first-in-class oral candidate.

• Target Markets

  • Autoimmune and inflammatory diseases (e.g., rheumatoid arthritis, sarcopenia)
  • Age-related muscle decline
  • Chronic pain and neurological conditions through the cannabinoid platform

• Industry Trends

  • Increasing focus on small-molecule therapies for improved administration
  • Utilization of AI and machine learning in patient stratification and trial design
  • Growing demand for treatments targeting underlying disease mechanisms

---

tl;dr

• TNF Pharmaceuticals (Nasdaq: TNFA) began trading under its current name on July 24, 2024.
• Stock increased by 34.56% to $0.2274 on June 10, 2025, with 6.06 million shares traded.
• Lead candidate MYMD-1® is progressing into mid-stage trials following a positive Phase 2 sarcopenia study in 2023.
• Cash balance of $5.88 M supports ongoing R&D; minimal debt on the balance sheet.
• Unique market position as the only oral TNF-α inhibitor in clinical development may drive future growth.